Fusion AntibodiesLSE:FAB 32 Market Cap is £14.39 Mil as of Jun. 29, 2026. GuruFocus rates LSE:FAB with a GF Score™ of 32/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,428 Biotechnology companies, Fusion Antibodies ranks worse than 76.68% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Fusion Antibodies's share price for the quarter that ended in Sep. 2025 was £0.175. Fusion Antibodies's Shares Outstanding (EOP) for the quarter that ended in Sep. 2025 was 113.66 Mil. Therefore, Fusion Antibodies's market cap for the quarter that ended in Sep. 2025 was £19.89 Mil.
Fusion Antibodies's quarterly market cap
increased
from Sep. 2024 (£4.03 Mil) to Mar. 2025 (£6.45 Mil) and
increased
from Mar. 2025 (£6.45 Mil) to Sep. 2025 (£19.89 Mil).
Fusion Antibodies's annual market cap
declined
from Mar. 2023 (£10.02 Mil) to Mar. 2024 (£3.58 Mil) but then
increased
from Mar. 2024 (£3.58 Mil) to Mar. 2025 (£6.45 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Fusion Antibodies's Enterprise Value for Today is £14.53 Mil.
Fusion Antibodies (LSE:FAB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Fusion Antibodies Market Cap Related Terms
Fusion Antibodies Market Cap Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FAB vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Fusion Antibodies's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Market Cap distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Fusion Antibodies's Market Cap for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies (LSE:FAB) has a Market Cap of £14.39 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Fusion Antibodies and its competitors. According to the industry distribution chart, Fusion Antibodies ranks #1095 out of 1428 companies in the Biotechnology industry, placing it in the top 76.7%.
Is Fusion Antibodies' Market Cap too high?
Fusion Antibodies' current Market Cap is £14.39 Mil. Based on the distribution chart, Fusion Antibodies ranks #1095 out of 1428 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fusion Antibodies has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #1095 out of 1428 companies for Market Cap. This places Fusion Antibodies in the lower half of its industry. The industry median Market Cap is 114.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Fusion Antibodies and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fusion Antibodies's current Market Cap is £14.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.12 — trading 187.5% above its estimated fair value. The current Market Cap is £14.39 Mil. Fusion Antibodies' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Market Cap is £14.39 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.12 is trading 187.5% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
Market Cap: £14.39 Mil
GF Value™: £0.04 vs. price of £0.12 (187.5% above fair value)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
32GF Score
Get the complete analysis for LSE:FAB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
